GLP-1 Side Effects: Clinical Overview

GLP-1 receptor agonists are widely used in weight management and metabolic care. While generally well tolerated, these medications are associated with a range of gastrointestinal and systemic effects, particularly during treatment initiation and dose escalation.

Common Gastrointestinal Side Effects

GLP-1 medications slow gastric emptying, which can lead to gastrointestinal symptoms. Commonly reported side effects include nausea, diarrhoea, bloating or early satiety, and dyspepsia or gastro-oesophageal reflux. These effects are typically mild to moderate in severity and often improve over time as patients adapt to treatment.

Nutritional Considerations and Muscle Preservation

Reduced appetite is a key mechanism of GLP-1 treatments and contributes to their effectiveness. However, this may result in reduced caloric intake, making nutritional quality particularly important. Adequate protein intake is recommended to support muscle mass during weight loss. While individual requirements vary, an intake in the region of 1.2–1.6 g/kg/day may be appropriate depending on clinical context and activity level. Lower targets may be required in patients with renal impairment, and clinical advice should be sought in these cases. Resistance-based exercise is also recommended to help preserve lean body mass. Temporary hair shedding may occur in some individuals, often associated with rapid weight loss or reduced nutrient intake, and is usually self-limiting.

Sulphur Burps and Gastrointestinal Gas

Some patients report sulphur burps, characterised by a sulphur-like odour or taste. These are caused by hydrogen sulphide gas produced during bacterial fermentation in the gastrointestinal tract. Delayed gastric emptying associated with GLP-1 therapy can increase the duration of food retention in the stomach, which may enhance bacterial fermentation, increase gas production, and lead to sulphur burps in some patients. These symptoms are most commonly observed during treatment initiation, following dose increases, and within the first few weeks of therapy. They are generally transient and resolve as physiological adaptation occurs.

Symptom Management Strategies

Several practical strategies may help reduce gastrointestinal symptoms. These include consuming smaller, more frequent meals, eating slowly and chewing food thoroughly, reducing intake of high-sulphur foods such as eggs, red meat, legumes and cruciferous vegetables where symptoms are problematic, avoiding carbonated beverages, maintaining adequate hydration, and considering peppermint-based remedies for symptomatic relief. Probiotics may be considered, although evidence is variable. If symptoms are persistent or poorly tolerated, dose adjustment or further clinical assessment may be required.

Rare but Serious Adverse Effects

Although uncommon, GLP-1 receptor agonists have been associated with more serious adverse events, including pancreatitis presenting as severe abdominal pain, and gallstones or gallbladder inflammation. Patients experiencing significant or persistent abdominal pain should seek medical attention promptly.

Summary

GLP-1 therapies are generally well tolerated, with most side effects being gastrointestinal, mild and transient. Appropriate patient education, nutritional support and dose management are key to optimising tolerability and treatment outcomes. Patients should be assessed on an individual basis to ensure safe and effective use of these medications within a broader weight management strategy.

If you are interested in weight loss support you can start a consultation here